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Abstract
Background: Obesity is a multifactorial disorder influenced by genetic and environmental factors. Animal models
of obesity are required to help us understand the signaling pathways underlying this condition. Zebrafish possess
many structural and functional similarities with humans and have been used to model various human diseases,
including a genetic model of obesity. The purpose of this study was to establish a zebrafish model of diet-induced
obesity (DIO).
Results: Zebrafish were assigned into two dietary groups. One group of zebrafish was overfed with Artemia (60
mg dry weight/day/fish), a living prey consisting of a relatively high amount of fat. The other group of zebrafish
was fed with Artemia sufficient to meet their energy requirements (5 mg dry weight/day/fish). Zebrafish were fed
under these dietary protocols for 8 weeks. The zebrafish overfed with Artemia exhibited increased body mass
index, which was calculated by dividing the body weight by the square of the body length, hypertriglyceridemia
and hepatosteatosis, unlike the control zebrafish. Calorie restriction for 2 weeks was applied to zebrafish after the
8-week overfeeding period. The increased body weight and plasma triglyceride level were improved by calorie
restriction. We also performed comparative transcriptome analysis of visceral adipose tissue from DIO zebrafish, DIO
rats, DIO mice and obese humans. This analysis revealed that obese zebrafish and mammals share common
pathophysiological pathways related to the coagulation cascade and lipid metabolism. Furthermore, several
regulators were identified in zebrafish and mammals, including APOH, IL-6 and IL-1b in the coagulation cascade,
and SREBF1, PPARa/g, NR1H3 and LEP in lipid metabolism.
Conclusion: We established a zebrafish model of DIO that shared common pathophysiological pathways with
mammalian obesity. The DIO zebrafish can be used to identify putative pharmacological targets and to test novel
drugs for the treatment of human obesity.
Background
According to the World Health Organization, an esti-
mated 310 million people worldwide are obese [1]. Such
estimates are particularly alarming given the strong
association between obesity and various adverse health
consequences, including atherosclerosis, hypertension,
type 2 diabetes and certain types of cancer [1-3]. While
the exact causes remain elusive, it is now accepted that
obesity is a complex, multifactorial disease that develops
from an interaction between the genotype and the envir-
onment [1,2,4].
A number of genes involved in monogenic, syndromic
and polygenic obesity have been identified [2,5]. In addi-
tion to genetic predisposition, environmental and beha-
vioral factors resulting in increased physical inactivity
and calorie intake also contribute to the development of
obesity [6]. Numerous studies in rodents have attempted
to characterize the functions of obesity-related genes and
whole-animal responses to high-calorie and high-fat diets
[7]. Such studies have generally shown that the obesity
phenotype can differ based on the functions of knockout
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This suggests the importance of developing and analyzing
genetic and diet-induced models of obesity.
Although rodent models have greatly contributed to
our understanding of human obesity [11], experiments
using rodent models require considerable staff and infra-
structural support, and are relatively expensive. There-
fore, the development of simple and inexpensive animal
models of obesity to complement the currently used
rodent models has been anticipated. Recent studies on
energy homeostasis in worms, fly and zebrafish have
shown that these lower organisms can be used to unravel
the metabolic processes underlying obesity [12,13].
As vertebrates, zebrafish possess many structural simila-
rities with humans that worms and flies do not [13] and
have been used to model various human diseases [14-19].
For example, zebrafish digestive organs, adipose tissues
(AT), and skeletal muscle are physically arranged in a
manner similar to their human counterparts [13]. Neural
and endocrine signals regulating food intake are also con-
served in zebrafish, including agouti-related protein
(AgRP) [15,20], leptin [21] and adiponectin [22]. Although
zebrafish larvae have been used in genetic and chemical
screening experiments to identify novel genes involved in
the regulation of energy homeostasis and potential thera-
peutic targets to treat obesity [13,23], it remains unclear
whether zebrafish can be used as a model for diet-induced
obesity (DIO), similar to that observed in mammals.
We have developed a zebrafish model for DIO and
validated the model by several methods, including bio-
chemical and histological analyses, diet therapies and
DNA microarray analysis of visceral AT with compari-
son to those of mammalian obesity. These studies
revealed that DIO zebrafish and obese mammals share
common pathophysiological pathways, suggesting that
zebrafish can be used as an alternative model of DIO.
Results
Zebrafish overfed with Artemia become obese
To develop a zebrafish model of DIO, we overfed the
fish with freshly hatched nauplii of brine shrimp Arte-
mia, a common food source for aquaculture [24]. Given
the hierarchy of macronutrient effects on the perception
of hunger (i.e. fat is least satiating while protein is most
satiating [4]), it is plausible that zebrafish would over-
feed on Artemia and become obese. Indeed, increases in
the amount of dietary fat are associated with the risk of
developing obesity [1,25].
We first assessed the consumption of Artemia by zeb-
rafish. It was previously reported that the energy
requirement for a Leopard Danio, a spotted color
morph of zebrafish, is under 30 cal [26]. Therefore, we
fed zebrafish at 3.5 months post-fertilization (mpf) with
5o r6 0m go ff r e s h l yh a t c h e dArtemia to meet their
energy requirements (control) or to overfeed (OF),
respectively. Zebrafish fed 5 or 60 mg of Artemia per
day consumed about 80 or 50% of the provided Artemia,
respectively (Methods). Because 1 mg of Artemia con-
tains approximately 5 calories, it was estimated that a
zebrafish would obtain 20 calories from 5 mg of Arte-
mia at 80% consumption, and 150 calories from 60 mg
of Artemia at 50% consumption. Zebrafish were fed
under these dietary protocols for 8 weeks.
As shown in Figures 1A and 1B, significant (p < 0.05)
increases in body mass index (BMI), which was calcu-
lated by dividing the body weight (g) by the square of the
body length (cm), were evident in male (1.1-fold) and
female (1.3-fold) zebrafish in the OF group compared
with those in the control group within 1 week of the diet-
ary protocol. This trend was maintained throughout the
8-week dietary protocol. As shown in Figures 1C and 1D,
plasma TG levels were also significantly (p < 0.05) higher
in male (2.4-fold) and female (1.8-fold) zebrafish in the
OF group than in the control group at week 8, but not at
week 1. Lipid-specific Oil Red O staining of frozen liver
sections revealed abnormalities consistent with hepatos-
teatosis in both male (Figure 1G) and female (Figure 1H)
zebrafish in the OF group at week 8, but not in the con-
trol group. These results indicate that zebrafish overfed
with Artemia develop obesity in a manner similar to
those observed in transgenic zebrafish overexpressing
AgRP [15] and in mammalian models of DIO [8].
Calorie restriction improved body weight and
hypertriglyceridemia
Calorie restriction (CR) is the most frequently prescribed
treatment for obesity, although the health benefits of CR
based on hard endpoints such as cardiovascular morbid-
ity and mortality remain to be elucidated [1]. To validate
the effect of CR, we fed the previously OF zebrafish with
2.5 mg of freshly hatched Artemia per day (50% of the
control level) for 2 weeks (CR2W) after the 8-week over-
feeding period (OF8W). The zebrafish consumed almost
all of the provided Artemia (Methods) and the body
weight of male and female zebrafish decreased to 84%
and 82%, respectively, at OF8W (Figures 2A and 2B).
Plasma TG levels were significantly (p < 0.05) decreased
to 69% 52% at OF8W in male and female, respectively
(Figures 2C and 2D). These data indicate that CR is effec-
tive for the treatment of DIO in zebrafish, similar to
mammalian DIO [6-8].
Gene expression profiling of visceral AT revealed
common pathways in obesity
It has been reported that visceral AT plays an active role
in the development of obesity-related complications
such as cardiovascular diseases, insulin resistance and
cancer [27]. Therefore, we performed DNA microarray
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visceral AT from zebrafish overfed Artemia for 1
(OF1W) or 8 (OF8W) weeks, and treated the zebrafish
with CR for 2 weeks (CR2W) after 8 weeks of overfeed-
ing. The amount of visceral AT in the control group
was so small that we could not extract total RNA.
Therefore, we compared the genome-wide expression
profiles of zebrafish at OF1W and OF8W to identify
genes dysregulated by overfeeding using Rank Product
Analysis (RankProd) [28]. RankProd analysis identified
Figure 1 Assessment of BMI, plasma TG and hepatic steatosis in zebrafish overfed with Artemia. Changes in BMI (g/cm
2) in male (A) and
female (B) zebrafish in the control and OF groups. Values are means ± SEM. OF group: n = 17 males and 16 females. Control group: n = 14
males and 17 females. Changes in plasma TG levels in male (C) and female (D) zebrafish in the control and OF groups. Values are means ± SEM.
OF group: n = 7 males and 8 females. Control group: n = 7 males and 9 females. Statistical analyses were performed using Student’s t-test to
compare the OF and control groups at each time-point. *P < 0.05, **P < 0.01. (E-H) Oil Red O staining of liver sections from a male (E) and
female (F) in the control group and a male (G) and female (H) in the OF group.
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[FDR] <15%) increased and decreased, respectively, at
OF8W [Additional file 1: Supplementary Table S1]. To
identify the genes ameliorated by CR, we compared the
genome-wide expression profiles of OF8W and CR2W.
Among the 168 genes dysregulated by overfeeding, 97
genes (58%) were significantly (FDR <15%) ameliorated
by CR [Additional file 2: Supplementary Table S2].
To compare the gene expression profiles of visceral AT
of zebrafish and mammalian DIO, we downloaded multi-
ple sets of microarray data from the Gene Expression
Omnibus [29] (Table 1). GSE8700 was designed to ana-
lyze the differences in epididymal AT gene expression in
rats fed a high-fat diet with those fed a control diet using
Affymetrix Rat Genome Arrays [30]. GSE11790 was
designed to analyze the differences in omental AT gene
expression in mice fed a high-fat diet with those fed a
control diet using custom arrays [31]. GSE15524 was
designed to analyze the differences in omental AT gene
expression in obese versus lean human individuals using
CodeLink Uniset Human Bioarrays [32].
We analyzed the microarray data using RankProd and
identified genes that were differentially expressed in
mammalian obesity. RankProd identified 461, 364 and
358 genes as being significantly (FDR <15%) dysregu-
lated in rat, mouse and human obesity, respectively
[Additional files 3, 4 and 5: Supplemental Tables S3,5].
We compared these gene lists with the 168 genes that
were significantly dysregulated in zebrafish DIO [Addi-
tional file 6: Supplemental Table S6]. One gene (fatty
acid binding protein 1, FABP1) was dysregulated in all
three models of mammalian obesity, but was not spotted
in the zebrafish microarray. Quantitative PCR (qPCR)
analysis of zebrafish fabp1a revealed a positive trend in
OF8W [Additional file 7: Supplemental Figure S1].
Fourteen genes were dysregulated in two models of
mammalian obesity, while 22 genes were dysregulated in
zebrafish DIO and in one model of mammalian obesity
Figure 2 Effects of calorie restriction on body weight and plasma TG level. Body weight is significantly decreased by CR for 2 weeks in
both male (A) and female (B) zebrafish. Values are means ± SEM. n = 7 for each group. The plasma TG level is significantly decreased by 2
weeks of CR in male (C) and female (D) zebrafish. Values are means ± SEM. n = 7 for each group. Statistical analyses were performed using
Student’s t-test to compare the OF8W and the OF8W+CR2W groups. *P < 0.05, **P < 0.01.
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sis confirmed the induction of hpx in OF8W compared
to OF1W [Additional file 7: Supplemental Figure S1].
Because the microarray platform differed among these
four datasets, it is plausible that the composition of the
gene list differs among these four species. Therefore, we
analyzed the microarray data using Gene Set Enrichment
Analysis (GSEA) [33] to identify gene sets defined based
on prior biological knowledge, such as the Gene Ontol-
ogy category. GSEA can determine whether members of
a gene set belonging to a same biological pathway tend
to occur toward the top of a given gene list, such as the
gene list established from microarray analysis. The GSEA
revealed that genes related to blood coagulation were sig-
nificantly dysregulated in zebrafish, rat and mouse DIO
and in human obesity. Genes related to platelet activa-
tion, fatty acid metabolism, cholesterol efflux, and trigly-
ceride metabolism were significantly dysregulated in
zebrafish, rat and mouse DIO (Table 2).
We also performed Sub-Network Enriched Analysis
(SNEA) [34] to identify key molecules regulating the
expression of the genes in the coagulation cascade or
lipid metabolism identified by GSEA. SNEA revealed
apolipoprotein H (APOH), interleukin-6 (IL-6) and
interleukin-1b (IL-1b) as regulatory molecules in the
coagulation cascade in obese zebrafish, rats, mice and
humans (Table 3). SNEA also revealed sterol regulatory
element binding transcription factor 1 (SREBF1), peroxi-
some proliferator-activated receptor alpha (PPARA),
nuclear receptor subfamily 1 group H member 3
(NR1H3), PPAR gamma (PPARG) and leptin (LEP) as
regulatory molecules involved in lipid metabolism in
obese zebrafish, rats, mice and humans (Table 3).
The interactions between these regulatory molecules
and their target genes are shown in Figure 3 for the
coagulation cascade and Figure 4 for lipid metabolism.
The color of many genes, including fibrinogen-g (FGG)
and factor II (F2, also known as thrombin) in Figure 3
and apolipoprotein A-I (APOA1) in Figure 4, are red,
suggesting that genes related to coagulation cascade and
lipid metabolism are induced by obesity. By contrast,
the color of these genes was turned green by CR, sug-
gesting that CR ameliorates dysfunctions in the coagula-
tion cascade and lipid metabolism (Figure 5). These
results suggest that DIO zebrafish share common patho-
physiological pathways with mammalian obesity.
Discussion
In this study, we developed a zebrafish model of DIO.
DIO zebrafish exhibited increased BMI, hypertriglyceri-
demia and hepatosteatosis. Comparative transcriptome
analysis using visceral AT revealed that the DIO zebra-
fish and obese mammals share common pathophysiolo-
gical pathways. These findings suggest that the DIO
zebrafish model can be used to identify putative phar-
macological targets and to test novel drugs for the treat-
ment of human obesity.
Zebrafish can be used as a useful animal model of DIO
The regulation of feeding behavior occurs via close
interactions between peripheral regions and the brain
[1-4,35-38]. Peripheral endocrine and metabolic factors
convey information regarding nutritional status to the
brain. The peripheral signals include satiety signals, such
as PYY [39], GLP-1 [40] and ghrelin [41], which origi-
nate from the gastrointestinal tract, as well as adiposity
signals, such as adiponectin [22] and insulin [42], the
blood levels of which are proportional to body nutrient
stores [38]. The brain then processes this peripheral
information and induces neuropeptide signaling
Table 1 Microarray datasets used for comparative transcriptome analysis
Dataset Species Adipose tissue Control Obesity
GSE18566 Zebrafish Intra-abdominal n = 4 (GSM461993-6) n = 4 (GSM461997-2000)
GSE8700 Rat Epididymal n = 8 (GSM215579-86) n = 7 (GSM215572-78)
GSE11790 Mouse Omental n = 4 (GSM298294-97) n = 5 (GSM298289-93)
GSE15524 Human Omental n = 3 (GSM388904, 905, 930) n = 11 (GSM388906-16)
Table 2 Enriched biological processes showing dysregulation in zebrafish and mammalian obesity
Zebrafish Rat Mouse Human
Process NES MC p-value NES MC p-value NES MC p-value NES MC p-value
Blood coagulation 2.3 3.1 0.0E+0 2.0 1.1 0.0E+0 1.7 1.1 9.5E-3 1.8 1.5 0.0E+0
Platelet activation 2.0 4.8 0.0E+0 1.8 1.1 6.1E-3 1.7 1.0 1.9E-2
Fatty acid metabolism 2.2 1.6 0.0E+0 1.8 1.0 0.0E+0 1.8 1.0 4.5E-3
Cholesterol efflux 1.6 1.1 0.0E+0 1.9 1.4 5.7E-3 1.8 1.3 0.0E+0
Triglyceride metabolism 1.8 2.0 0.0E+0 1.8 1.2 5.8E-3 1.7 1.1 9.5E-3
NES: normalized enrichment score; MC: median change in gene expression in the gene set.
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orexin [44]), mainly from the hypothalamus, to stimulate
or inhibit feeding. These peripheral and central factors
controlling food intake are well conserved in zebrafish
[20,22,39-45].
Probably because of the low satiating effect of fat con-
sumption [4], high dietary fat intake is associated with
an increased risk of obesity [1,25]. Because of the rela-
tively high fat content in Artemia,a sc o m p a r e dw i t h
flake foods, we fed the zebrafish a diet consisting solely
of Artemia to induce obesity. We have demonstrated
that zebrafish overfed with Artemia showed significant
increases in BMI and plasma TG levels and hepatostea-
tosis, consistent with obesity observed in humans and
rodent models of DIO [1,6,7]. Of note, there seemed to
be no decrease in physical activity in the zebrafish over-
fed Artemia (data not shown), indicating that the devel-
o p m e n to fo b e s i t yi sm o s tl i k e l yt ob ear e s u l to ft h e
increased intake of a high-fat diet.
There are several advantages to the DIO zebrafish
model. First, zebrafish (AB line) respond well to the
Artemia diet because almost all of the zebrafish overfed
Artemia developed obesity. The C57BL/6J (B6) line has
been widely used for DIO in mice because these mice
are very susceptible to obesity when fed a high-fat diet
[6-9]. However, there are variations in adiposity among
individual B6 mice [46,47]. Similarly, when outbred
Sprague-Dawley rats are fed a high-fat diet, about half
become obese, while the other half are resistant to DIO
[6-10]. The relatively homogenous responses of zebrafish
to overfeeding with Artemia suggest that these fish
represent an excellent alternative model species for
experimental research on DIO. Furthermore, the dietary
protocol to induce obesity in zebrafish is simple and can
be applied to other zebrafish lines. For example, we are
currently applying the protocol to the Casper line,
which have transparent abdomens, even in the adult
stage [48]. Using DIO Casper zebrafish, visceral AT can
be visualized in a living animal under a fluorescent
microscope by staining the AT with a fluorescent dye,
such as Nile Red [49]. This feature makes it possible to
monitor the short- and long-term effects of a therapeu-
tic intervention on the amount of visceral AT in live
DIO zebrafish. Finally, zebrafish are small and easy to
maintain in large stocks because of their high fecundity,
thus making zebrafish amenable for medium-to-high
throughput screening for early drug discovery [50].
One limitation of the zebrafish DIO model is the
apparent absence of brown AT [51]. The development
of obesity in mammals not only depends on the balance
between food intake and calorie utilization, but also on
the balance between white AT and brown AT [51].
Therefore, zebrafish DIO may not be suitable to identify
signaling pathways related to brown AT.
Comparative transcriptomics of visceral AT revealed
common pathophysiological pathways in zebrafish and
mammalian obesity
Genome-wide expression assays using DNA microarrays
allow rapid screening and quantification of differences
in large groups of functionally related genes and are
thus well-suited to studies of pathways dysregulated in
obesity [52]. We compared the visceral AT expression
profiles of zebrafish, rat, mouse and human obesity. The
comparative transcriptome analysis revealed that several
genes involved in blood coagulation, platelet activation,
fatty acid metabolism, cholesterol efflux, and triglyceride
metabolism were dysregulated in both zebrafish and
Table 3 Regulatory factors involved in the coagulation cascade and lipid metabolism in zebrafish and mammalian
obesity
Coagulation cascade Zebrafish Rat Mouse Human
Regulatory factor p-value Rank
a p-value Rank
a p-value Rank
a p-value Rank
a
APOH 1.9E-08 1 8.4E-16 1 2.4E-12 2 9.1E-11 4
IL-6 4.6E-05 3 6.5E-10 5 8.2E-09 7 4.5E-10 6
IL-1b 7.0E-05 6 1.2E-08 8 1.6E-07 16 8.4E-09 9
Lipid metabolism Zebrafish Rat Mouse Human
Regulatory factor p-value Rank
a p-value Rank
a p-value Rank
a p-value Rank
a
PPARa 1.6E-10 1 1.1E-23 1 9.1E-19 1 6.9E-24 1
PPARg 1.7E-10 2 1.7E-15 3 2.1E-14 2 1.1E-16 3
NR1H3 1.0E-06 5 1.6E-15 2 2.7E-12 5 5.8E-17 2
LEP 1.8E-05 9 4.1E-10 13 3.7E-09 8 3.6E-12 10
SREBF1 1.8E-03 36 2.8E-13 7 5.7E-10 7 9.9E-10 15
aRegulatory factors are ranked based on the p-value in each dataset.
Regulatory factors ranked within the top 15 in at least three datasets are shown in this table.
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fied as regulatory factors involved in blood coagulation
and platelet activation in zebrafish and mammalian obe-
sity. Similarly, SREBP1, PPARa/g, NR3H1 and LEP were
identified as common regulatory factors for fatty acid
metabolism, cholesterol efflux and triglyceride metabo-
lism in zebrafish and mammalian obesity.
Visceral AT dysfunction can play a causal role in the
prothrombotic state observed in obesity by affecting
hemostasis, coagulation and fibrinolysis [53-55]. It has
also been shown that IL-6 and IL-1b, secreted from
visceral AT, induce the biosynthesis of fibrinogen from
visceral AT and liver. Fibrinogen is a substrate of F2
(thrombin) in the final step of the coagulation cascade,
and its presence is essential for platelet aggregation [53].
Of interest, plasma fibrinogen levels were found to be
significantly higher in obese subjects than in age- and
sex-matched non-obese individuals [53]. Significant cor-
relations have been reported between fibrinogen and
BMI and the waist-to-hip ratio [53]. It has also been
Figure 3 Network for the coagulation cascade. The network shows direct interactions between the three key regulatory molecules (IL-6, IL-1b
and APOH, shown in yellow) identified by SNEA (Table 3) and their target genes in the coagulation cascade (blood coagulation and platelet
activation) identified by GSEA (Table 2). Red and green denote genes with increased and decreased expression, respectively, in obese (OF8W)
compared with control (OF1W) zebrafish. Gray denotes genes that were not spotted in the microarray. To reduce the complexity, the rat, mouse
and human networks were constructed using the three regulatory factors and their target genes that were spotted in Agilent Zebrafish
Oligoarray. A. zebrafish DIO (GSE18566), B. rat DIO (GSE8700), C. mouse DIO (GSE11790), D. human obesity (GSE15524).
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Page 7 of 13Figure 4 Network for lipid metabolic pathways. The network shows direct interactions between the five key regulatory molecules (SREBP1,
PPARa/g, NR3H1 and LEP, shown in yellow) identified by SNEA (Table 3) and their target genes involved in the lipid metabolic pathways (fatty
acid metabolism, cholesterol efflux and triglyceride metabolism) identified by GSEA (Table 2). Red and green denote genes with increased and
decreased expression, respectively, in obese (OF8W) compared with control (OF1W) zebrafish. Gray denotes genes that were not spotted in the
microarray. To reduce the complexity, the rat, mouse and human networks were constructed using the five regulatory factors and their target
genes that were spotted in the Agilent Zebrafish Oligoarray. A. zebrafish DIO (GSE18566), B. rat DIO (GSE8700), C. mouse DIO (GSE11790),
D. human obesity (GSE15524).
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levels more effectively than modest weight reduction
[53]. Consistent with these reports, OF and CR signifi-
cantly induced and reduced, respectively, the expression
of fibrinogen in zebrafish (Figures 3A and 5A, Addi-
tional files 1 and 2: Supplemental Table S1 and S2).
APOH binds to activated protein C (APC), an anticoa-
gulant enzyme that is activated by activation of the pro-
tein C zymogen by the thrombin-thrombomodulin
complex on the surface of endothelial cells, platelets and
monocytes [56]. However, the effect of APOH binding
to APC is inconclusive and the functional role of APOH
in obesity remains to be elucidated.
Dyslipidemia is commonly seen in obesity [57,58] and is
characterized by an increased flux of free fatty acids, ele-
vated TG levels, low high-density lipoprotein cholesterol
levels and increased low-density lipoprotein levels [57].
Fatty acid metabolism, cholesterol efflux and triglyceride
metabolism are closely related to these pathways. This
study revealed that SREBP1, PPARa/g, NR3H1 and LEP
are key regulatory factors in these pathways and are
expressed in zebrafish and mammalian obesity. PPARs
mediate adaptive metabolic responses to increased sys-
temic lipid availability and are activated by endogenous or
dietary lipids [59]. PPARa promotes lipid clearance by
increasing tissue fat oxidization [59,60] while PPARg pro-
motes lipid storage in white AT, as well as preadipocyte
differentiation to mature adipocytes [59]. SREBP1 is an
important transcription factor that regulates the transcrip-
tion of many lipid genes and participates in adipocyte dif-
ferentiation by stimulating PPARg [61,62]. NR3H1, also
known as liver X receptor A (LXRA), has been shown to
regulate lipid and carbohydrate homeostasis [63]. LEP, an
adiposity hormone produced by white AT, reflects total fat
mass [64]. Although we did not detect a statistically signif-
icant difference between OF8W and OF1W in terms of
the mRNA expression level of lep measured by qPCR
(data not shown), the expression of apoa1, a transcrip-
tional target gene of leptin [65], was significantly induced
and reduced by OF and CR, respectively (Figures 4A and
5B) [Additional files 1, 2 and 7: Supplemental Tables S1
and S2, and Figure S1], suggesting that leptin protein
levels were likely to be increased in zebrafish DIO. It is
noteworthy that the functional importance of SREBP1,
PPARa/g, NR3H1 and LEP in obesity has been shown in
many genetic studies [2,11,63,66].
Conclusions
Here, we have shown that the DIO zebrafish model
shares common pathophysiological pathways with
Figure 5 Effects of CR on the coagulation cascade and lipid metabolism in DIO zebrafish. A. Network showing direct interactions between the
three key regulatory molecules (IL-6, IL-1b and APOH, shown in yellow) identified by SNEA (Table 3) and their target genes in the coagulation cascade
(blood coagulation and platelet activation) identified by GSEA (Table 2). B. Network showing direct interactions between the five key regulatory
molecules (SREBP1, PPARa/g, NR3H1 and LEP, shown in yellow) identified by SNEA (Table 3) and their target genes involved in the lipid metabolic
pathways (fatty acid metabolism, cholesterol efflux and triglyceride metabolism) identified by GSEA (Table 2). Red and green denote genes with
increased and decreased expression, respectively, at CR2W compared with OF1W. Gray denotes genes that were not spotted in the microarray.
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pharmacological targets of human obesity. For example,
we are currently performing genome-wide expression
profiling of the DIO zebrafish liver. The zebrafish model
can also be used to study the hypothalamic-pituitary
axis, the main link between the central nervous and the
endocrine system [67]. Further studies are needed to
examine whether complications related to obesity such
as insulin resistance, cardiovascular diseases and cancer
can be studied in DIO zebrafish.
Methods
Feeding zebrafish
Adult zebrafish (AB line, ZIRC, Eugene, OR, USA) were
kept at 28°C under a 14-h light:10-h dark cycle, and
water conditions of environmental quality were main-
tained according to an established protocol [68]. Zebra-
fish at 3.5 mpf were assigned into two dietary groups
(overfeeding and maintenance groups) with approxi-
mately five fish per 2-L tank. Zebrafish in the overfeeding
group were fed three times per day with freshly hatched
Artemia (corresponding to 60 mg cysts/fish/day). Zebra-
fish in the maintenance group were fed freshly hatched
Artemia (corresponding to 5 mg cysts/fish/day) once per
day. For calorie restriction, the zebrafish were fed freshly
hatched Artemia (corresponding to 2.5 mg cysts/fish/
day) for 2 weeks after being overfed for 8 weeks. Com-
mercial flake food (Hikari Tropical Fancy Guppy, Kyorin,
Hyogo, Japan) consists of 9% fat, 17% carbohydrate and
59% protein, whereas Artemia nauplii consist of 22% fat,
16% carbohydrate and 44% protein (dry weight basis).
The percentage of consumed Artemia was estimated
by counting Artemia before and after feeding. Briefly, 1
mL of water was collected from 1700 mL of water con-
taining freshly hatched Artemia corresponding to 100 or
8.5 mg cysts. The numbers of hatched Artemia were
counted three times to determine a mean count. After
counting, the samples were returned to the 2-L tank.
Then, five fish were transferred to the tank for feeding.
After 2 hours, the number of Artemia was counted as
before feeding. Zebrafish fed 5 or 60 mg of Artemia per
day consumed about 80 or 50% of the provided Artemia,
respectively. Zebrafish fed 2.5 mg of Artemia per day
consumed almost all of the provided Artemia.
Measurement of BMI and plasma TG
The body weight and length of zebrafish were measured
weekly throughout the study. Zebrafish length was mea-
sured from the head to the end of the body. Blood was
withdrawn from the dorsal artery of the zebrafish at the
indicated times after an overnight fast to measure
plasma TG (TG L-type assay, Wako, Tokyo, Japan).
Oil Red O staining
Zebrafish were fixed using 4% formaldehyde solution in
PBS. The fixed samples were rapidly frozen in liquid
nitrogen-cooled isopentane, embedded in Tissue-Tek
(Sakura Finetek Europe, Zoeterwoude, Netherlands) and
cut using a cryostat. After drying, the sections were
fixed in 4% formalin and rinsed with distilled water. The
sections were then immersed in a working solution of
Oil Red O (Wako) for 15 min and rinsed with distilled
water. Sections were also counterstained using Mayer’s
hematoxylin to visualize the nuclei.
Nile Red staining
A stock solution of Nile Red (Wako) was prepared by
dissolving 10 mg of Nile Red in 10 mL acetone. Zebra-
fish were transferred into 1000 mL of swimming water
containing 100 μg of Nile Red and incubated overnight
in the dark at 28°C. After incubation, the fish were
rinsed in fresh water and observed with a fluorescence
microscope (MZ 16F, Leica, Tokyo, Japan) using a GFP2
filter (Leica).
DNA microarray analysis of visceral AT of DIO zebrafish
The visceral (omental) AT of male DIO zebrafish
stained with Nile Red was collected by surgical extrac-
tion under a fluorescence microscope. The AT was
stored in RNA-later (Applied Biosystems, Foster City,
CA, USA). Total RNA was then extracted using an
RNeasy Mini Kit (Qiagen, Valencia, CA, USA), quali-
fied by an Agilent Bioanalyzer 2100 (Agilent, Santa
Clara, CA, USA) and quantified using a spectrophot-
ometer (NanoDrop ND-100, Wilmington, DE, USA).
Three hundred nanograms of total RNA from each
visceral AT depot were converted into labeled cRNA
using the Low RNA Input Fluorescent Linear Amplifi-
cation Kit (Agilent). Cy3-labeled cRNA (1.5 μg) was
hybridized to Agilent Zebrafish Whole Genome Oligo
Microarrays (G2518A) according to the manufacturer’s
protocol. The microarray has 22,000 different probes.
Each probe is spotted twice distantly in a microarray.
The hybridized microarrays were scanned (Agilent
G2565BA) and analyzed using Feature Extraction soft-
ware (Agilent). The data were normalized according to
the manufacturer’s protocol (Agilent). RankProd analy-
sis [28] was performed using Bioconductor [69] to
identify differentially expressed genes between two
groups by calculating the FDR. Differentially expressed
genes (FDR <15% for both duplicated probes) were
then converted to human orthologs using the Life
Science Knowledge Bank (World Fusion, Tokyo,
Japan). The gene symbols of human orthologs were
used for functional analysis.
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T h em i c r o a r r a yd a t a( [ G E O : G D S 8 7 0 0 ][ 3 0 ] ,[ G E O :
GSE11790] [31] and [GEO;GSE15524] [32]) were down-
loaded from Gene Expression Omnibus [29]. We used
microarray data that were filtered and normalized and
applied the data to RankProd analysis [28] to identify
differentially expressed genes between obese and control
mammals. The conversion to human orthologs and
functional analysis were performed as described above
for visceral AT from DIO zebrafish. The microarray
data of zebrafish DIO have been deposited in NCBI
GEO and can be downloaded from GEO main page
(http://www.ncbi.nlm.nih.gov/geo/) with accession num-
ber GSE18566. GSEA and SNEA were performed using
Pathway Studio 7 (Ariadne Genomics, Rockville, MD,
USA). Pathway Studio is a program used to visualize
and analyze biological pathways and gene regulation
networks. This program includes the ResNet database of
more than 500,000 functional relationships and the
MedScan tool for automatic extraction of information
from the scientific literature. Pathway Studio 7 draws
networks based on the extracted information and was
used to draw Figures 3, 4 and 5.
GSEA was used to determine the list of biological
pathways dysregulated in obesity using the Kolmogorov-
Smirnov enrichment algorithm with 400 random permu-
tations to determine statistical significance. SNEA was
used to identify molecules regulating expression of
genes in the coagulation cascade (blood coagulation and
platelet activation) and in lipid metabolism (fatty acid
metabolism, cholesterol efflux and triglyceride metabo-
lism), both of which were identified by GSEA to be dys-
regulated in zebrafish and mammalian obesity. SNEA
built sub-networks of genes related to the coagulation
cascade or the lipid metabolism and identified the cen-
tral “seed” of each network prioritized by the p-value
based on the criterion “Expression Targets” in the
ResNet database.
qPCR analysis
Total RNAs from zebrafish visceral AT were used to
generate cDNAs using an iScript Select cDNA Synthesis
Kit (Bio-Rad, Hercules, CA, USA). qPCR was done
using an ABI Prism 7300 (Life Technologies, Carlsbad,
CA, USA) with SYBR Green Realtime PCR Master Mix
Plus (Toyobo, Osaka, Japan). The thermal cycling condi-
tion comprised an initial step at 95°C for 1 min followed
by 40 cycles of 95°C for 15 sec, 60°C for 15 sec and
72°C for 45 sec. The primers used in this study are
shown in [Additional file 8: Supplementary Table S7].
Data were normalized by the quantity of glyceraldehyde-
3-phosphate dehydrogenase (gapdh). This allowed us to
account for any variability in the initial template
concentration as well as the conversion efficiency of the
reverse transcription reaction.
Statistical Analysis
Results are expressed as means ± SEM. Differences
between groups were tested for statistical significance
using Student’s t-test.
Additional material
Additional file 1: Supplemental Table S1. Genes dysregulated in DIO
zebrafish (OF8W vs OF1W)
Additional file 2: Supplemental Table S2. Genes ameliorated by CR in
zebrafish DIO (CR2W vs OF8W)
Additional file 3: Supplemental Table S3. Genes dysregulated in DIO
rats (GSE8700)
Additional file 4: Supplemental Table S4. Genes dysregulated in DIO
mice (GSE11790)
Additional file 5: Supplemental Table S5. Genes dysregulated in obese
humans (GSE15524)
Additional file 6: Supplemental Table S6. Genes differentially
expressed in visceral AT in the same direction in at least two obesity
models
Additional file 7: Supplemental Figure S1. Validation of the differential
gene expression by qPCR analysis. Total RNA was extracted from
zebrafish visceral AT and qPCR analysis was performed to validate the
differential expression identified by microarray analysis. Results represent
means ± S.E.M. of each group. P-value was calculated by Student’s t-test
using OF1W (N = 6) vs. OF8W (N = 4). *p < 0.05.
Additional file 8: Supplemental Table S7. Primers used in qPCR
analysis
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